Evotec SE (EVO) Q3 2026 Earnings Call Transcript

Evotec reported Q3 2026 revenue of EUR 164.9 million, broadly stable year over year, while adjusted EBITDA improved to a loss of EUR 1.6 million from EUR 15.0 million, supported by lower costs and Project Horizon savings. Nine-month revenue fell 13.1% to EUR 465.0 million and adjusted EBITDA worsened to a loss of EUR 44.3 million; management nevertheless reaffirmed FY 2026 guidance and expects revenue of EUR 570–610 million and adjusted EBITDA of negative EUR 105–70 million toward the upper ends of those ranges. Project Horizon targets EUR 75 million in annual run-rate savings by end-2027, with more than 20% delivered by September, and Vertex selected Evotec’s J.POD Redmond facility for commercial manufacturing of povetacicept. A planned manufacturing pause during Redmond’s third-train installation is expected to weigh on 2027 manufacturing revenue.

Analysis

The key tension is improving leading indicators versus still-unproven earnings conversion. D&PD base-business net sales and leads are strengthening, but nine-month revenue and EBITDA remain materially weaker; the commercial funnel has value only if it converts into billable work without further delays. Q3 near-break-even EBITDA is a poor run-rate anchor: management cited roughly €30m of milestone-related contribution, with less expected in Q4, so the reaffirmed full-year range implies a substantial sequential setback. That makes the next guidance update more informative than the headline Q3 improvement.

JEB’s Vertex selection improves customer validation and capacity visibility, but does not eliminate execution risk: Redmond’s planned manufacturing pause creates a 2027 revenue headwind just as the facility is meant to scale. The Nov. 13 PDUFA date is an immediate catalyst for the customer program, not proof of Evotec revenue; timing and commercial supply remain dependent on approval, readiness, and ramp. Meanwhile, €91.9m of reorganization costs and declining liquidity make cash conversion—not adjusted savings claims—the test of whether Horizon protects the balance sheet.

The contrarian angle is that the announced pipeline and 2030 mix ambition may draw attention away from near-term phasing and utilization. Conversely, the market may underweight the operating leverage if D&PD conversion normalizes and JEB fills capacity. The relevant falsifiers are further slippage in D&PD conversion, weaker-than-guided FY EBITDA, cash/liquidity deterioration, or delays to Vertex supply and the Redmond expansion.

Key Decisions for Investors

• Avoid chasing EVO solely on Q3 EBITDA: milestone-related contribution makes the quarter a weak proxy for recurring profitability. Reassess after FY results and the 2027 outlook clarify conversion, utilization, and cash use.
• Keep EVO on a catalyst watch through the Nov. 13 PDUFA date and subsequent supply updates. Treat approval as validation for Vertex’s program, not as confirmation of near-term Evotec sales; the investment case needs disclosed timing and contribution.
• For an existing EVO position, focus on cash/liquidity and operating cash flow alongside Horizon savings. Escalate downside risk if liquidity continues to erode without measurable EBITDA improvement, or if guidance falls below the currently indicated upper-end trajectory.
• No compelling read-through trade in VRTX, JAZZ, ODTX, or SDZ from this call alone: the disclosed relationships do not establish material near-term earnings sensitivity for those companies.